Psychedelic Research in
American Samoa
American Samoa is a low-signal territory or non-sovereign geography in Blossom's country database. Blossom does not currently link this page to psychedelic clinical trials, stakeholders, or events, so it should be read as a database placeholder rather than a mature research profile.
Key Insights
A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in American Samoa.
- 1
Blossom currently tracks no country-linked psychedelic clinical trials for American Samoa.
- 2
Blossom currently tracks no linked psychedelic stakeholders or events for American Samoa.
- 3
No verified country-specific psychedelic access pathway is recorded in this lightweight page content.
- 4
Future updates should prioritise verified trial registrations, regulator or health-ministry sources, and locally based organisations before adding more detailed claims.
Research Snapshot
Blossom currently keeps American Samoa as a country index, but no psychedelic clinical trials, stakeholders or events are linked to this country in the database yet.
Missing linked records are database coverage signals, not proof that no local policy discussion, care or informal activity exists.
- Active trials
- 0
- Total trials
- 0
- Stakeholders
- 0
- Events
- 0
None marked active
No linked trials
No linked stakeholders
No linked events
Top Compounds
No headline compound signal is available from linked country trials yet.
Top Study Topics
No study-topic signal is available from linked country trials yet.
Medical Access Snapshot
American Samoa treats most classic psychedelics (psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca, mescaline, 2C-X) as controlled/hallucinogenic substances with criminal penalties and no routine medical access outside of approved research. FDA-approved prescription products that are controlled (e.g., esketamine/SPRAVATO and medically-authorized ketamine for anesthesia) may be available under U.S. federal regulatory frameworks, but territory Medicaid and reimbursement arrangements are administered under territory-specific rules and can be more...
Regulatory Status
No country-specific psychedelic access review has been completed for American Samoa. Readers should not infer legal medical availability, reimbursement, or private clinical access from this placeholder; any access question should be checked compound by compound against current local law and medicines regulation.
Country Details
- Region
- Oceania
- Last updated
- 4 May 2026
Country Report
Strictly Illegal (except regulated prescription products/clinical research)Medical Access and Reimbursement
American Samoa treats most classic psychedelics (psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca, mescaline, 2C-X) as controlled/hallucinogenic substances with criminal penalties and no routine medical access outside of approved research. FDA-approved prescription products that are controlled...
Open access guide →